Monica Sifuentes

Learn More
Recombinant human alpha-L-iduronidase (Aldurazyme, laronidase) was approved as an enzyme replacement therapy for patients with the lysosomal storage disorder, mucopolysaccharidosis I (MPS I). In order to assess the long-term safety and efficacy of laronidase therapy, 5 of 10 patients in the original laronidase Phase 1/2 clinical trial were re-evaluated(More)
STUDY OBJECTIVES To identify behavioral, environmental, and sociodemographic risk factors associated with non-fatal firearm injuries among inner city adolescents in the United States. DESIGN A case-control study in which patients with firearm injury serve as cases and those with medical conditions serve as controls. SETTING A level I trauma center in a(More)
  • 1